Floatz logo

Mitoxantrone

Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Rapamycin
Fred Hutchinson Cancer Center
Phase 2B
Monomethyl Fumarate
Fred Hutchinson Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →